Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Eventide Asset Management LLC

Eventide Asset Management LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 272,954 shares of the biotechnology company's stock after acquiring an additional 44,425 shares during the quarter. Eventide Asset Management LLC owned about 0.29% of Sarepta Therapeutics worth $34,089,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Captrust Financial Advisors grew its stake in Sarepta Therapeutics by 15.2% during the 3rd quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company's stock valued at $483,000 after acquiring an additional 511 shares in the last quarter. Taconic Capital Advisors LP purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $624,000. Summit Partners Public Asset Management LLC grew its position in shares of Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock valued at $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Alkeon Capital Management LLC lifted its position in Sarepta Therapeutics by 13.4% during the third quarter. Alkeon Capital Management LLC now owns 633,845 shares of the biotechnology company's stock worth $79,161,000 after buying an additional 75,000 shares in the last quarter. Finally, Blueshift Asset Management LLC acquired a new position in Sarepta Therapeutics during the third quarter worth $262,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SRPT. UBS Group raised their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Raymond James reaffirmed an "outperform" rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Barclays reduced their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. Finally, Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $4.60 on Friday, reaching $133.34. The stock had a trading volume of 777,554 shares, compared to its average volume of 1,246,366. The stock has a market cap of $12.74 billion, a P/E ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The business's 50-day moving average price is $122.50 and its 200 day moving average price is $131.49. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.